1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660.HK
AIM Vaccine Co., Ltd.HK flagHong Kong Stock Exchange
1.50
HKD
-0.14
- -
1.84BMarket Cap
AIM Vaccine Co., Ltd.
6660.HK
(Hong Kong Stock Exchange)

Recent

price

1.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
0.79
1.35
1.3
1.05
0.98
1.06
0.95
Revenue per Share
0.1
0.31
-0.57
-0.27
-1.07
-0.23
-0.55
Basic EPS, GAAP
-0.02
-0.34
-0.87
-0.8
-0.39
-0.11
-0.14
Free Cash Flow per Basic Share
0.07
- -
- -
- -
- -
- -
- -
Dividend per Share
0.7
0.92
0.99
1.01
1
1
1
Book Value per Share
0.82
2.34
2.5
2.61
2.32
1.94
1.43
Tangible Book Value per Share
1,210
1,210
1,210
1,203
1,211
1,211
1,224
Basic Weighted Avg Shares
952
1,638
1,570
1,264
1,187
1,285
1,166
Sales/Revenue/Turnover
17.62
29.62
-38.43
-30.15
-37.95
-16.41
-16.47
Operating Margin (%)
109
128
144
166
175
172
158
Depreciation Expense
117
379
-693
-320
-1,301
-277
-675
Net Income, GAAP
23.57
17.59
- -
- -
- -
- -
- -
Effective Tax Rate (%)
12.34
23.16
-44.12
-25.28
-109.56
-21.57
-57.95
Profit Margin (%)
155
1,307
789
299
-119
-703
-1,050
Working Capital
51
47
226
369
569
434
357
LT Debt
1,618
3,422
5,699
5,861
3,890
3,611
2,937
Total Equity
- -
14.03
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
28.67
- -
- -
- -
- -
- -
Return on Capital (%)
- -
38.69
-59.98
-26.51
-107.43
-22.89
-55.42
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.99%
-18.68%
Free Cash Flow
- -
9.03%
23.23%
Net Income, GAAP
- -
7.1%
143.64%
Sales/Revenue/Turnover
- -
-6.15%
-9.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,187
2024
- -
- -
- -
- -
1,285
2025
- -
- -
- -
- -
1,166

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.07
2024
- -
- -
- -
- -
-0.23
2025
- -
- -
- -
- -
-0.55

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
WPD Pharmaceuticals Inc. (WPDPF)
Agios Pharmaceuticals, Inc. (AGIO)
Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
AlloVir, Inc. (ALVR)
Ionis Pharmaceuticals, Inc. (0JDI.L)
Business
AIM Vaccine Co., Ltd. (6660.HK) engages in the research, development, manufacturing, and commercialization of human vaccines across China and select international markets, operating a full industrial chain with five validated vaccine technology platforms. Founded through acquisitions dating back to 2004 and restructured in 2020 with headquarters in Beijing, China, the company offers eight commercialized products targeting six diseases, including recombinant hepatitis B vaccine (Hansenula polymorpha, AIM Hanxin), freeze-dried human rabies vaccine (Vero cell, Rong'an Bio), inactivated hepatitis A vaccine (human diploid cell, AIM Kanghuai), live attenuated mumps vaccine (AIM Weixin), bivalent inactivated haemorrhagic fever with renal syndrome vaccine (Vero cell, AIM Weixin), and ACYW135 meningococcal polysaccharide vaccine (MPSV4, AIM Weixin); its subsidiaries encompass four wholly-owned manufacturing entities and three research institutes, with products distributed to 31 Chinese provinces and exported to regions such as Egypt, Pakistan, Southeast Asia, Africa, South America, and the Middle East. Recent developments include the 2024 Phase III completion and production license for the iterative serum-free rabies vaccine with market registration application accepted by China's NMPA in April 2025, alongside clinical trial approvals in 2025 for iterative-process highly-effective human diploid rabies vaccine, mRNA respiratory syncytial virus vaccine and mRNA herpes zoster vaccine by both U.S. FDA and China's NMPA, Phase III completion for 13-valent pneumococcal conjugate vaccine (PCV13) with marketing application submitted, full integration of DeepSeek AI across operations in February 2025 for lifecycle efficiency gains, and a narrowed net loss of 85-87% to RMB250-290 million on RMB1.25-1.3 billion revenue for 2024. The pipeline features 21 innovative vaccines for 13 diseases covering global top-10 categories, such as tetravalent meningococcal conjugate vaccine (MCV4), PCV13/PCV20/pneumococcal polysaccharide vaccines, mRNA COVID-19 variants, DTP combinations, influenza vaccines (MDCK cells), and EV71-CA16 bivalent hand-foot-mouth disease vaccine.